

1 **Title: Point-of-care lung ultrasound predicts severe disease and death due to COVID-19: a**
2 **prospective cohort study.**

3 **Authors:** Paul W. Blair, MD^{1,2*,**}, Trishul Siddharthan, MD^{3,4**}, Gigi Liu, MD⁵, Jiawei Bai,
4 PhD⁶, Joshua East, RPSGT⁴, Phabiola Herrera, MD³, Lalaine Anova, MS¹, Varun Mahadevan⁴,
5 Shakir Hossen, MBBS⁴, Stefanie Seo, BS⁷, Olamide Sonuga, BS⁷, Joshua Lawrence, BS⁷, Jillian
6 Peters, MD⁵, Andrea Cox, MD², Yukari C. Manabe, MD², Katherine Fenstermacher, PhD⁷,
7 Sophia Shea, MPH⁷, Richard E. Rothman, MD, PhD⁷, Bhakti Hansoti, MD⁷, Lauren Sauer, MS⁷,
8 Ciprian Crainiceanu, PhD⁶, Danielle V. Clark, PhD¹.

9 Affiliation:

10 ¹The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD;

11 ²Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD

12 ³Division of Pulmonary and Critical Care Medicine, University of Miami, Miami, FL

13 ⁴Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of
14 Medicine, Baltimore, MD

15 ⁵Division of General Internal Medicine, Johns Hopkins University School of Medicine,
16 Baltimore, MD

17 ⁶Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore MD

18 ⁷Department of Emergency Medicine, Johns Hopkins University, Baltimore MD.

19

20 *Corresponding Author: Paul W. Blair, MD MSPH MHS. Henry M. Jackson Foundation for the
21 Advancement of Military Medicine. 6720A Rockledge Dr, Bethesda, MD 20817. E-mail:

22 pblair@aceso-sepsis.org

23 **Co-first authors.

- 24 Reprints: Reprints are not being ordered for this manuscript
- 25 Performance institution: Johns Hopkins University School of Medicine
- 26 Financial support: This project was supported by Joint Program Executive Office (JPEO-EB)
- 27 W911QY-20-9-0004 (2020 OTA) and the Johns Hopkins University School of Medicine
- 28 COVID-19 Research Fund.
- 29 Word count: 2,999
- 30 Abstract Word count: 296
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46

47 **Abstract**

48 **Objective:** The clinical utility of point-of-care lung ultrasound (LUS) for disease severity triage
49 of hospitalized patients with COVID-19 is unclear.

50 **Design:** Prospective cohort study

51 **Setting:** A large tertiary care center in Maryland, USA between April 2020 to September 2021.

52 **Patients:** Hospitalized adults (≥ 18 years of age) with positive SARS-CoV-2 RT-PCR results.

53 **Interventions:** None.

54 **Measurements and Main Results:** All patients were scanned using a standardized protocol
55 including 12 lung zones and followed to determine clinical outcomes until hospital discharge and
56 vital status at 28-days. Ultrasounds were independently reviewed for lung and pleural line
57 artifacts and abnormalities, and the mean Lung Ultrasound Score (ranging from 0 to 3) across
58 lung zones (mLUSS) was determined. The primary outcome was time to ICU-level care, defined
59 as high flow oxygen, noninvasive, or mechanical ventilation, within 28-days of the initial
60 ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for
61 mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the
62 median age was 59 years and 114 (43.2) % of participants were female. The median mLUSS was
63 1 (interquartile range: 0.5 to 1.3). Following enrollment, 29 (11.0%) participants went on to
64 require ICU-level care and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at
65 enrollment was associated with disease progression to ICU-level care (aHR = 3.63; 95% CI: 1.23
66 to 10.65) and 28-day mortality (aHR = 4.50; 95% CI: 1.52 to 13.31). Pleural line abnormalities
67 were independently associated with disease progression to ICU-level care (aHR = 18.86; CI:
68 1.57 to 226.09).

69 **Conclusions:** Participants with a mLUSS ≥ 1 or pleural line changes on LUS had an increased
70 likelihood of subsequent requirement of high flow oxygen or greater. LUS is a promising tool for
71 assessing risk of COVID-19 progression at the bedside.

72 **Key words:** COVID-19, Ultrasonography, SARS-CoV-2, Survival Analysis, Cohort Studies

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92 **Introduction**

93 Point-of-care lung ultrasound (LUS) has been used for the evaluation of a range of
94 cardiopulmonary conditions in emergency and critical care settings though, to date,
95 implementation protocols have varied across settings. LUS offers benefits over traditional
96 imaging modalities including portability, instantaneous results, lower costs, and lack of exposure
97 to ionizing radiation. LUS has been proposed as an essential tool in evaluating patients with
98 coronavirus disease 2019 (COVID-19) pneumonia to prevent nosocomial spread of disease.(1)
99 Ultrasound hardware can be cleaned easily and reduces the burden on personnel and resources
100 that would be required for traditional chest imaging. LUS may be able to identify patients at risk
101 for decompensation requiring higher level of care in resource-limited settings or in regions with
102 limited ICU capacity during a COVID-19 surge.

103
104 Despite the potential utility of LUS in COVID-19 management, standardized and evidence-based
105 clinical use has not been fully established. The most widely studied and reported findings are
106 based on the LUS score, originally developed in 2011 and used for assessment of aeration for
107 titration of positive end-expiratory pressure (PEEP) (2). This scoring system includes a 0 to 3
108 point grade per 6 lung zones totaled from each hemithorax (3). This has been adopted for
109 prognostication for non-COVID-19 acute respiratory distress syndrome (4) and was subsequently
110 evaluated as a part of candidate models for COVID-19 prognostication (5-9). Among individuals
111 with COVID-19, the LUS score has been associated with relevant chest CT findings and predicts
112 the extent of parenchymal disease as well as mortality.(5) However, modified scores have
113 limitations and have not been widely adopted. Modifications to scores had been based on early
114 anecdotal reports and resulted in multiple scoring systems without protocol standardization and

115 unclear generalizability. The LUS scores predicate on being able to sum all 12 zones, which can
116 be challenging to obtain in tenuous patients in prone position.

117
118 The aim of this study was to determine the association between baseline lung ultrasound findings
119 and the ultimate oxygen support requirements or death. We used a mean LUS (mLUSS) rather
120 than a sum to determine the utility of the original and most studied LUS score (2) for COVID-19
121 prognostication with the added flexibility to include less than 12 lung zones. We performed a
122 survival analysis with Cox regression mLUSS to determine risk of subsequently requiring ICU-
123 level care (i.e., either high flow oxygen, noninvasive, or invasive ventilation) as a primary
124 outcome. Secondary outcomes included ventilation plus 28-day death or 28-day death alone. We
125 hypothesized that the mLUSS would be associated with an increased risk of progression to
126 requiring ICU-level care.

127

128 **Methods**

129 We enrolled adults (≥ 18 years of age) who tested positive for SARS-CoV-2 on RT-PCR and
130 were admitted to Johns Hopkins Hospital in Baltimore, Maryland into a larger COVID-19
131 prospective cohort after verbal informed consent, between April 2020 to September 2021 as a
132 convenience sample. This protocol was approved by the Johns Hopkins University Institutional
133 Review Board (IRB00245545). Participants were enrolled after admission throughout the
134 enrollment period or from the emergency department starting December 2020. After screening
135 2,270 patients, 723 participants enrolled into the master protocol, and 264 of these participants
136 had LUS performed as part of study procedures depending on LUS-trained research staff
137 availability.

138

139 LUS was standardized with 6-second clips from 12 lung zones with six lung zones on each side
140 as previously described.(10) All images were collected with a Lumify S4 phased array probe
141 (Philips, Amsterdam, Netherlands) using the application's lung scan settings. We employed a
142 standardized, point-of-care ultrasound (POCUS) research protocol to characterize lung
143 abnormalities in COVID-19. Study personnel received training by a clinician certified in critical
144 care ultrasonography and reviewed the initial ultrasound scanning sessions until operators were
145 proficient. Study personnel were subsequently masked to clinical information and recorded LUS
146 reads identifying and characterizing A lines (Figure 1A), B lines (Figure 1B and 1C), pleural
147 effusions (Figure 1D), pleural line abnormalities (Figure 1E), and consolidations (Figure 1F).
148 The pleural line was considered abnormal if it was irregular, fragmented, discontinuous, or ≥ 0.5
149 cm in thickness. Consolidations were required to be ≥ 0.25 cm in at least one dimension. While
150 hospitalized, study visits including lung ultrasound scans occurred on study days 0, 3, 7, and
151 weekly for up to 90 days. The first available scan was used for this analysis. Baseline
152 demographics, comorbid conditions, and oxygen requirements until discharge were determined
153 using the Hopkins Precision Medicine Analytics Platform (11), and duration of symptoms at
154 enrollment was determined through medical chart review. Date of death by 28 days from
155 enrollment was determined using the Precision Medicine Analytics Platform, medical chart
156 review, and review of the regional Maryland, Washington D.C, and Virginia health information
157 exchange (12).

158

159 As previously described (13), the LUS score was calculated for each zone with 1 point for
160 discrete B lines, 2 points for coalescent B lines, and 3 points for lung consolidation. The mean

161 LUS score (mLUSS) ranges from 0 to 3, with a higher score signifying higher severity. The
162 mLUSS was calculated out of total available zones to include participants with missing zones.
163 The Pearson correlation coefficient of the mLUSS between masked ultrasound clip readers was
164 determined for the participants that were available (61 consecutive patients or 23% of the
165 cohort). Participants were divided into severity groups at baseline based on severity at the time of
166 POCUS or peak severity prior to POCUS: on room air or nasal cannula supplemental oxygen
167 (moderate disease), on HFNC or noninvasive positive pressure ventilation (NIPPV) (moderately
168 severe), or on mechanical ventilation (severe disease). Summary statistics were performed by
169 comparing baseline demographics (i.e., sex, age, race, ethnicity, medical comorbidities), and
170 duration post symptom-onset between severity groups using Kruskal-Wallis tests.

171

172 Progression to ICU-level care was defined as newly requiring either high flow nasal cannula,
173 noninvasive ventilation, or mechanical ventilation during the hospitalization. To determine the
174 association between baseline LUS characteristics and future risk, this outcome was restricted to
175 study participants not requiring more than supplemental oxygen via low-flow nasal cannula at
176 baseline (among those with moderate disease at baseline, N=164) (Figure 2). Secondary
177 outcomes included 28-day mortality (all baseline severity groups, N=264) and 28-day
178 progression to mechanical ventilation or 28-day death (among those with moderate or
179 moderately severe disease, N=215) (Figure 2). A Kaplan-Meier plot was created to compare risk
180 over time between those at the 25th and 75th mLUSS percentile. After checking the proportional
181 hazards assumption, Cox proportional hazards regression models were used to evaluate the
182 differences in risk of death and risk of death or subsequent mechanical ventilation plus 28-day
183 death as a function of baseline % of lung fields with A lines, % with B lines, % with

184 consolidations, % with pleural line abnormalities, % with pleural effusions, or the mLUSS.
185 Unadjusted analyses and analyses adjusting for age and biologic sex were performed. A
186 sensitivity analysis of the model including age, sex, and mLUSS covariates was performed
187 restricting the population to those with all 12 lung zones for each of the primary and secondary
188 outcomes. An additional sensitivity analysis was performed excluding 16 participants that were
189 asymptomatic. Data were analyzed in R (v4.0.2) and Stata, version 16.0 (StataCorp LLC,
190 College Station, TX, USA).

191

192 **Results**

193 Of 264 participants, the median age was 61 (interquartile range [IQR], 48 to 68 years) and 43.0%
194 (n = 114) were female (Table 1). The study participants were racially and ethnically diverse with
195 47.9% (n=127) of the population identified as black and 16.6% (n = 44) identified as Hispanic.
196 The median time from symptoms onset until ultrasound scan was 9.29 days (IQR, 5.15 to 14.31
197 days) and the median mLUSS at baseline was 1.00 (IQR, 0.50 – 1.30) overall. Comorbid illness
198 was common. The majority (74.2%) of participants had hypertension and 42.4% participants had
199 diabetes mellitus (Table 1). Diagnoses of congestive heart failure (33.0%) and chronic
200 obstructive pulmonary disease (36.4%) were also common. Most participants were overweight
201 (median 30.0 kg/m²; IQR: 25.4 to 33.2). At baseline, 169 participants required only ambient
202 oxygen or nasal cannula supplemental oxygen, and an additional 46 participants (18.7%) were
203 requiring high flow nasal cannula (HFNC) or non-invasive positive pressure ventilation
204 (NIPPV). (Table 1) Lastly, 40 participants (16.3%) required mechanical ventilation at the time of
205 initial ultrasound scanning. During hospitalization, the most frequent treatments included
206 dexamethasone (63.6% of participants), remdesivir (50.0%), or tocilizumab (9.1%).

207

208 *Baseline cross-sectional differences in POCUS findings by severity*

209 At enrollment, participants with severe illness were later in their course of illness (median: 15.79
210 days post symptom onset; IQR: 10.92 to 26.70 days) compared to those with moderately severe
211 (median: 9.29 days; IQR: 7.03 to 13.92 days), or moderate illness (median 7.38 days; IQR 4.08
212 to 11.92 days) (Table 2). A lines were the most common finding among lung zones scanned
213 (median 75.0% of lung fields; IQR, 58.3 to 91.7%), with a stepwise decrease in proportion of
214 lung zones affected in moderately severe disease (median 69.7%; IQR, 51.8 to 87.1%) followed
215 by severe disease at enrollment (54.6%; IQR, 25.0 to 66.7%) (Table 2). B lines were more likely
216 to be present among those with severe disease (median 75.0%; IQR, 60.0 to 100%) or
217 moderately severe disease (median 81.8%; IQR, 67.9 to 100%) compared to moderate cases
218 (median 57.1%; IQR, 27.3 to 75.0%). Similarly, participants requiring mechanical ventilation at
219 enrollment had higher percent of pleural line abnormalities (median 25.0%; IQR, 9.1 to 50)
220 compared to moderately severe (median 0.0%; 0.0 to 15.6%) or moderate (median 0.0%; IQR
221 0.0 to 16.7%) disease. The mLUSS was lower for moderate disease (median 0.83; IQR, 0.33 to
222 0.80) compared to a stepwise increase in moderately severe disease (median 1.11; IQR, 1.00 to
223 1.50) followed by severe critical disease (1.25; IQR, 1.00 to 1.67). The Pearson correlation
224 coefficient of the mLUSS between readers was high at 0.77 among 61 participants with a an
225 available matched masked LUS read (Supplemental Figure S1).

226

227 *Risk of disease progression*

228 When evaluating the 28-day risk of progression to severe COVID-19, multiple baseline POCUS
229 parameters were found to be associated with severity progression using Cox proportional hazards

230 regression. Each point increase in the mLUSS was associated with disease progression to ICU-
231 level care (aHR = 3.61; 95% CI: 1.27 to 10.22) and 28-day mortality (aHR = 3.10; 95% CI: 1.29
232 to 7.50), but not the composite outcome of ventilation or death (aHR = 2.45; 95% CI 0.81 to
233 11.02) (Figure 3 and Figure 4). Inference was unchanged when adjusting for total number of
234 available lung zones with an increased risk of progression to ICU-level care (aHR = 3.80; 95%
235 CI: 1.32 to 10.95) or death (aHR: 2.47; 95% CI: 1.10, 5.55), but not the composite outcome of
236 ventilation or death (aHR: 2.96; 95% CI: 0.80 to 11.01). Similarly, inference was unchanged
237 when excluding asymptomatic individuals with each increase in the mLUSS associated with risk
238 of progression to ICU-level care (aHR = 3.07; 95% CI: 1.04 to 9.07), death (aHR: 2.94; 95% CI:
239 1.21 to 7.15), but not ventilation or death together (aHR: 2.69; 95% CI: 0.66 to 11.05). Lastly,
240 when including days since symptom onset, there was an increased risk with each additional day
241 (aHR: 1.007; 95% CI: 1.001 to 1.01), but the risk associated with each increase in mLUSS was
242 similar (aHR: 3.86; 95% CI: 1.32 to 11.30) (Supplemental Table S1). There was no interaction
243 observed between duration of symptoms and mLUSS (p=0.48) (data not shown).

244
245 Individual lung ultrasound characteristics were associated with disease progression. The
246 presence of any type of B line was not associated with an increased risk of progression to ICU-
247 level care (among those not on NIPPV, HFNC, or mechanical ventilation) (adjusted hazard ratio
248 [aHR] = 2.75; 95% confidence interval [CI], 0.45 to 16.71) but was associated with 28-day
249 mortality compared to those without any B lines (aHR = 13.43; 95% CI, 1.24 to 145.79) (Figure
250 4; Supplemental Table S1). Except for A lines, all studied individual POCUS parameters (i.e., B
251 lines, pleural line changes, consolidations, and pleural effusions) had an increased risk of
252 progression to ICU-level care, death, and death or ventilation but did not always meet statistical

253 significance. Accordingly, A lines, which are generally present in the absence of B lines, were
254 associated with a decreased risk of progression to ICU-level care (aHR 0.10; 95% CI, 0.02 to
255 0.69) and 28-day mortality (aHR = 0.10; 95% CI, 0.02- 0.63). Pleural abnormalities were
256 independently associated with mechanical ventilation plus death (aHR = 21.78; 95% CI, 1.30 to
257 365.95), and death (pleural line aHR = 20.93; 95% CI, 3.34 to 131.30).

258

259 **Discussion**

260 We observed mLUSS and multiple individual LUS findings were associated with a subsequent
261 increased oxygen requirement or death in a prospective cohort. Our results support LUS to
262 identify hospitalized patients that may need a higher level of care or transport to centers with
263 ICU beds available. While many studies to date have used retrospective clinical data, we
264 conducted a prospective cohort study with standardized time points, probes, and protocols for
265 image acquisition. The findings of this study support the use of lung ultrasound as a clinical tool
266 that can improve triage by using individual POCUS abnormalities or mLUSS. Participants with
267 more A lines on LUS are less likely to clinically deteriorate and participants with irregular
268 pleural lines were more likely to have or to require higher levels of care. The mLUSS correlated
269 well between ultrasound readers and could be used for patients with difficult to scan lung zones.
270 These findings demonstrate the prognostic value of individual LUS findings or the mLUSS in
271 assessing anticipated disease severity trajectories of COVID-19 without necessarily requiring all
272 12 lung zones.

273

274 Although there have been few large studies (5, 8), LUS has been shown to be associated with
275 radiographic and clinical severity among adults hospitalized with COVID-19. Nouvenne et al.

276 demonstrated B lines, pleural line irregularities and large parenchymal consolidations with
277 correlated with CT findings and oxygen saturation.(14) In a systematic review of 43 studies the
278 presence of focal, multifocal and/or confluent B lines and the presence of pleural irregularities
279 were common among individuals with COVID-19.(15) Mechanistically, the degree and
280 magnitude of LUS abnormalities throughout lung zones reflects the extent of lung disease and is
281 intuitively directly related to severe disease trajectories. In one of the largest studies to date with
282 matched CT scans, LUS compared to CT as a gold standard for severe COVID-19 had an area
283 under the curve of 0.78 (CI 95% 0.68–0.87; $p < 0.001$). (16) Rubio-Garcia and colleagues
284 examined the LUS among 130 patients with COVID 19 and demonstrated an increased risk of
285 mortality among individuals with a high modified LUS score (HR 5.25, 0.84–32.84) (9). The
286 investigators however did not describe individual features of the LUS such as A lines, B lines
287 and pleural disease and used a high cutoff to optimize sensitivity (9). While other studies have
288 generally used a sum of all 12 lung zones (5, 8, 9, 17), our study found the risk estimates were
289 unchanged when some lung fields were not obtainable due to clinical instability. Our study is
290 consistent with prior publications and provides evidence that LUS can prognosticate hospitalized
291 patients using available lung zones.

292
293 Adoption of LUS has varied in hospital settings largely a result of lack of familiarity as well as
294 difference in approaches, techniques, and nomenclature (18). However, research personnel in our
295 study were taught lung ultrasound using standardized protocols without prior experience.

296 Ultrasound images were overread by multiple reviewers and correlated well. Most ultrasound
297 operators were research coordinators who had no experience with ultrasound scanning prior to
298 training for this study. This provided standardization of scans and reduced bias related to direct

299 performance by medical caregivers. This suggests that LUS scanning could be expanded to non-
300 clinicians, including but not limited to nursing staff, respiratory therapists, or medics in the field.
301 For example, respiratory therapists or nursing staff could routinely perform LUS scans to obtain
302 and document this valuable information, similar to lung auscultation performed at some centers.
303 Alternatively, ultrasound technicians would be well-equipped to perform LUS scans with a
304 standardized read by radiology. While the value of immediate information to a performing
305 clinician should not be ignored or undervalued, extending the expertise of LUS performance to
306 additional healthcare workers would be more scalable than LUS by clinicians alone.

307
308 Biomarker and therapeutic research has identified the importance of phase of disease as indicated
309 by duration of symptoms (19). However, inference was unchanged after adjusting for duration of
310 symptoms or interaction with duration in our Cox regression models. POCUS results appeared to
311 be generalizable regardless of adjustment for days since symptom onset for determining risk of
312 decompensation towards ICU-level care. Change in LUS findings were not evaluated here due to
313 a limited sample size of repeat time events (data not shown), but studies are ongoing to evaluate
314 longitudinal LUS for estimating risk of severe disease and treatment response.

315
316 There were limitations to the present study. First, not all participants were enrolled prior to
317 admission, and as this was a hospital-based protocol, generally had a minimum requirement of
318 oxygen. Patients were not always enrolled on the day of admission which may have diminished
319 the effect size of differences in POCUS findings. Additionally, those hospitalized with incidental
320 asymptomatic SARS-CoV-2 infection may be less comparable to those with moderate severity,
321 but a sensitivity analysis was performed and inference about risk was unchanged. These factors

322 led to sample size limitations in some of the survival analyses leading to wide confidence
323 intervals, but the qualitative inference was consistent across outcomes and remains important.
324 Further work is ongoing in ambulatory settings and additional sites with standardized follow-up
325 to improve our understanding of the external validity and diagnostic accuracy among additional
326 populations including non-hospitalized individuals with COVID 19. Lastly, while the mLUSS
327 provide valuable prognostic information, additional lung ultrasound features such as
328 consolidations or pleural line changes appear to be useful prognostic findings and should be
329 evaluated for incorporation into models with subsequent validation. Future research with
330 machine learning and unsupervised approaches can help optimize LUS for clinical use.

331

332 **Conclusion**

333 Individual LUS findings and the mLUSS across available lung zones on lung POCUS are
334 associated with ultimate oxygen requirement or death, independent of duration of illness among
335 hospitalized patients.

336

337 Acknowledgments: We thank the participants within the CCPSEI cohort study.

338 Potential conflicts of interest: Y.C.M. receives research funding from Becton Dickinson,

339 Quanterix, and Hologic and receives funding support to Johns Hopkins University from

340 miDiagnostics.

341 Conferences: This analysis has not been previously presented.

342 Disclaimer: The contents of this article are the sole responsibility of the authors and do not

343 necessarily reflect the views, assertions, opinions, or policies of the Henry M. Jackson

344 Foundation for the Advancement of Military Medicine, Inc., the U.S. Department of Defense, the

345 U.S. government, or any other government or agency. Mention of trade names, commercial
346 products, or organizations does not imply endorsement by the U.S. government. The
347 investigators have adhered to the policies for protection of human subjects as prescribed in 45
348 CFR 46.

349

350 **References**

- 351 1. Buonsenso D, Pata D, Chiaretti A: COVID-19 outbreak: less stethoscope, more
352 ultrasound. *Lancet Respir Med* 2020
- 353 2. Bouhemad B, Brisson H, Le-Guen M, et al: Bedside ultrasound assessment of positive
354 end-expiratory pressure-induced lung recruitment. *Am J Respir Crit Care Med* 2011; 183(3):341-
355 347
- 356 3. Ampuero J, Sánchez Y, García-Lozano MR, et al: Impact of liver injury on the severity
357 of COVID-19: a systematic review with meta-analysis. *Rev Esp Enferm Dig* 2021; 113(2):125-
358 135
- 359 4. Zhao Z, Jiang L, Xi X, et al: Prognostic value of extravascular lung water assessed with
360 lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome.
361 *BMC Pulm Med* 2015; 15:98
- 362 5. de Alencar JCG, Marchini JFM, Marino LO, et al: Lung ultrasound score predicts
363 outcomes in COVID-19 patients admitted to the emergency department. *Ann Intensive Care*
364 2021; 11(1):6
- 365 6. Brahier T, Meuwly JY, Pantet O, et al: Lung ultrasonography for risk stratification in
366 patients with COVID-19: a prospective observational cohort study. *Clin Infect Dis* 2020

- 367 7. Alharthy A, Faqihi F, Abuhamdah M, et al: Prospective Longitudinal Evaluation of
368 Point-of-Care Lung Ultrasound in Critically Ill Patients With Severe COVID-19 Pneumonia. *J*
369 *Ultrasound Med* 2020
- 370 8. Ji L, Cao C, Gao Y, et al: Prognostic value of bedside lung ultrasound score in patients
371 with COVID-19. *Crit Care* 2020; 24(1):700
- 372 9. Rubio-Gracia J, Giménez-López I, Garcés-Horna V, et al: Point-of-care lung ultrasound
373 assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective
374 noninterventional study. *Eur Respir J* 2021; 58(3)
- 375 10. Soldati G, Smargiassi A, Inchingolo R, et al: Proposal for International Standardization
376 of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative,
377 Reproducible Method. *J Ultrasound Med* 2020; 39(7):1413-1419
- 378 11. inHealth JH: PMAP: The Johns Hopkins Precision Medicine Analytics Platform.
379 Available at: <https://pm.jh.edu/>. Accessed December 30, 2021
- 380 12. Gryczynski J, Nordeck CD, Martin RD, et al: Leveraging health information exchange
381 for clinical research: Extreme underreporting of hospital service utilization among patients with
382 substance use disorders. *Drug Alcohol Depend* 2020; 212:107992
- 383 13. Soummer A, Perbet S, Brisson H, et al: Ultrasound assessment of lung aeration loss
384 during a successful weaning trial predicts postextubation distress*. *Crit Care Med* 2012;
385 40(7):2064-2072
- 386 14. Nouvenne A, Zani MD, Milanese G, et al: Lung Ultrasound in COVID-19 Pneumonia:
387 Correlations with Chest CT on Hospital admission. *Respiration* 2020; 99(7):617-624
- 388 15. Peixoto AO, Costa RM, Uzun R, et al: Applicability of lung ultrasound in COVID-19
389 diagnosis and evaluation of the disease progression: A systematic review. *Pulmonology* 2021

- 390 16. Zieleskiewicz L, Markarian T, Lopez A, et al: Comparative study of lung ultrasound and
391 chest computed tomography scan in the assessment of severity of confirmed COVID-19
392 pneumonia. *Intensive Care Med* 2020; 46(9):1707-1713
- 393 17. Lichter Y, Topilsky Y, Taieb P, et al: Lung ultrasound predicts clinical course and
394 outcomes in COVID-19 patients. *Intensive Care Med* 2020; 46(10):1873-1883
- 395 18. Volpicelli G, Elbarbary M, Blaivas M, et al: International evidence-based
396 recommendations for point-of-care lung ultrasound. *Intensive Care Med* 2012; 38(4):577-591
- 397 19. Datta SD, Talwar A, Lee JT: A Proposed Framework and Timeline of the Spectrum of
398 Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
399 Implications. *JAMA* 2020; 324(22):2251-2252

400

401

402 Figure legends.







403 **Figure 1.** Lung ultrasound characteristics. 1A: A lines (arrows) are shown indicating normal
404 lung aeration; 1B: discrete B lines (arrows), implicating subpleural interstitial edema; 1C: a
405 coalesced B line (arrow); 1D: a small pleural effusion (arrow); 1E: fragmented pleural line
406 (arrow); 1F: a subpleural consolidation (arrow).


407 **Figure 2.** Flow diagram of enrollments and total participants included in survival analyses.

408 **Figure 3.** Kaplan-Meier time to progression by 75th percentile (1.3) vs 25th percentile (0.5)
409 mLUSS scores from time of lung ultrasound scan.


410 **Figure 4.** Forest Plot of hazard ratios of LUS parameters from individually fit models adjusting
411 for age and sex for progression to severe disease.

412


A**B****C****D****E****F**




A Progression to ICU-level care



B Progression to ventilation or death



C Progression to death



mLUSS = 0.5 mLUSS = 1.3 Unadjusted

Covariate **aHR**

Progress to ICU-level care

mLUSS 3.61

A-line (%) 0.10

B-line (%) 2.75

Pleural line abnormalities (%) 10.16

Consolidation (%) 19.18

Pleural effusion (%) 45.46

Progress to ventilation or death

mLUSS 2.99

A-line (%) 0.22

B-line (%) 2.13

Pleural line abnormalities (%) 21.78

Consolidation (%) 58.29

Pleural effusion (%) 16.09

Progress to death

mLUSS 3.10

A-line (%) 0.10

B-line (%) 13.43

Pleural line abnormalities (%) 20.93

Consolidation (%) 6.47

Pleural effusion (%) 13.84




Table 1. Participant baseline demographics.

Characteristic	Total (N=264)
Age —years, median (IQR)	58.56 (48.75, 68.00)
Female — no. (%)	114 (43.18)
Race — no. (%)	
Asian	7 (2.65)
Black	126 (47.73)
White	80 (30.30)
Other	49 (18.46)
Ethnicity — no. (%)	
Hispanic	44 (16.67)
Non-Hispanic	220 (83.33)
Smoking — no. (%)	
Never	149 (56.44%)
Current	23 (8.71%)
Former	80 (30.30%)
Median BMI — kg/m², median (IQR)	30.00 (25.4, 33.2)
Comorbidities — no. (%)	
Cancer	25 (9.5)
Congestive heart failure	87 (33.0)
COPD	96 (36.4)
Diabetes	112 (42.4)
Hypertension	196 (74.2)
HIV/AIDS	12 (4.6)
Liver Disease	54 (20.5)
Symptoms onset until LUS Scan — days, median (IQR)	9.29 (5.2, 14.3)
Total lung zones scanned — median (IQR)	9 (7, 12)
mLUS Score — median (IQR)	1.00 (0.50, 1.30)
A-line lung fields — %, median (IQR)	0.75 (0.58, 0.92)
B-line lung fields — %, median (IQR)	0.67 (0.38, 0.84)
Pleural Line abnormality lung fields — %, median (IQR)	0.00 (0.00, 0.18)

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score

Table 2. Cross-sectional differences in lung ultrasound findings by severity at baseline.

Oxygen requirement severity at baseline scan	Moderate: Ambient or low-flow nasal cannula (N=169)	Moderately Severe: High flow nasal cannula or NIPPV (N=46)	Severe: Ventilation at LUS (N=49)	p-value†
Age—years, median (IQR)	57.8 (46.00, 68.00)	61.30 (55.25, 69.00)	58.57 (53.00, 67.00)	<0.001
Female — no. (%)	84 (49.70)	18 (39.13)	12 (24.49)	0.006
Race — no. (%)				0.584
Asian	1 (0.59)	5 (10.87)	1 (2.04)	
Black	92 (54.44)	18 (39.13)	16 (32.65)	
White	49 (28.99)	15 (32.61)	16 (32.65)	
Other	26 (15.38)	8 (17.39)	15 (30.61)	
Ethnicity — no. (%)				0.445
Hispanic	25 (14.79)	8 (17.39)	11 (22.44)	
Non-Hispanic	144 (85.21)	38 (82.61)	38 (77.55)	
Median BMI — kg/m ² , median (IQR)	29.03 (24.18, 32.88)	31.22 (26.75, 33.17)	31.83 (27.05, 34.58)	0.054
Comorbidities — no. (%)				
Cancer	20 (11.83)	0 (0.00)	5 (10.20)	0.051
Congestive heart failure	50 (29.59)	15 (32.61)	22 (44.90)	0.141
COPD	65 (38.46)	15 (32.61)	16 (32.65)	0.620
Hypertension	125 (73.96)	35 (76.09)	36 (73.47)	0.957
Liver Disease	32 (18.93)	11 (23.91)	11 (22.45)	0.720
Diabetes	69 (40.83)	19 (41.30)	24 (48.98)	0.605
HIV/AIDS	8 (4.73)	4 (8.70)	0 (0.00)	0.126
Symptoms onset until LUS Scan — days, median (IQR)	7.38 (4.08, 11.92)	9.29 (7.03, 13.92)	15.79 (10.92, 26.70)	<0.001
mLUS Score — median (IQR)	0.83 (0.33, 0.80)	1.11 (1.00, 1.50)	1.25 (1.00, 1.67)	<0.001
A-line lung fields — %, median (IQR)	0.86 (0.67, 1.00)	0.697 (0.518, 0.87)	0.546 (0.25, 0.67)	<0.001
B-line lung fields — %, median (IQR)	0.57 (0.27, 0.75)	0.82 (0.68, 1.00)	0.750 (0.60, 1.00)	<0.001
Pleural Line abnormality lung fields — %, median (IQR)	0.00 (0.00, 0.17)	0.000 (0.00, 0.16)	0.25 (0.09, 0.50)	<0.001

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score

†Kruskal-Wallis test by ranks